| Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic Y Sun, M Ho Antibody therapeutics 3 (4), 246-256, 2020 | 41 | 2020 |
| Identification of a novel inhibitor against Middle East respiratory syndrome coronavirus Y Sun, H Zhang, J Shi, Z Zhang, R Gong Viruses 9 (9), 255, 2017 | 36 | 2017 |
| Dual roles of a novel oncolytic viral vector-based SARS-CoV-2 vaccine: Preventing COVID-19 and treating tumor progression Y Sun, W Dong, L Tian, Y Rao, C Qin, SA Jaramillo, EW Settles, S Ma, ... bioRxiv, 2021.06. 07.447286, 2021 | 3 | 2021 |
| Emerging Antibodies in Cancer Therapy Y Sun, J Xu Advanced NanoBiomed Research 3 (1), 2200083, 2023 | 2 | 2023 |
| Prefusion-Stabilized Lassa Virus Trimer Identifies Neutralizing Nanobodies and Reveals an Apex-Situated Site of Vulnerability J Gorman, CSF Cheung, Z Duan, Y Sun, P Wang, JC Boyington, A Biju, ... bioRxiv, 2022.04. 21.488985, 2022 | 2 | 2022 |
| Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability J Gorman, CSF Cheung, Z Duan, L Ou, M Wang, X Chen, C Cheng, A Biju, ... Nature Communications 15 (1), 285, 2024 | 1 | 2024 |
| Humanization of the Shark VNAR Single Domain Antibody Using CDR Grafting YF Zhang, Y Sun, J Hong, M Ho Current Protocols 3 (1), e630, 2023 | 1 | 2023 |
| Development of Anti-HIV Therapeutics: From Conventional Drug Discovery to Cutting-Edge Technology Y Sun, L Wang Preprints, 2024 | | 2024 |
